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Contraindicated Drugs
Tetracycline
Doxycycline
Primaquine
Tafenoquine
Halofantrine
Drugs thought to be safe
Azithromycin
Chloroquine
Clindamycin (usually paired with quinine or 
quinidine; rarely used in Africa)
Dapsone
– (+ pyrimethamine = Maloprim)
– (+ chlorproguanil = Lapdap)
Mefloquine (prophylaxis)
Proguanil, chlorproguanil (usually paired 
with other drugs)
Pyrimethamine (usually given as SP)
Quinine, quinidine (risk of hypoglycemia)
Sulfonamides (usually given as SP)
Drugs with questionable safety or 
limited data
Amodiaquine (no data)
Artemisinins
Atovaquone-proguanil (Malarone) (limited data)
Lapdap (chlorproguanil-dapsone) (limited data)
Lumefantrine (component of Coartem) (no data)
Mefloquine (treatment dose)
Combination therapy
– Amodiaquine-SP (no data)
– Artemisinin derivative with other drugs
AS+SP; AS+AQ; piperaquine + dihydroartemisinin; 
lumefantrine+artemether.
Newman et al, Tropical Medicine and International Health, 2003
Management of uncomplicated 
malaria in pregnancy
In areas with CQ and SP resistance (Kenya)
– 1st trimester
Quinine 10mg salt three times daily + clindamycin* 
(10mg/kg twice daily) for 7 days.
– 2nd and 3rd trimester
ACT known to be effective in the region  (ART/LUM , AQ/AS) 
OR
Artesunate plus clindamycin* (10mg/kg twice daily) for  7 
days  OR
Quinine plus clindamycin*  - both drugs given for 7 days
– If clindamycin is unavailable or unaffordable then quinine 
monotherapy may be given
Artemether-lumefantrine in 
pregancy
Artemisinins associated with teratogenicity, embryolethality, 
and foetal death in rats and rabbits 
Teratogenic effects include neuro, cardiac anomalies
More time of exposure related than dose related
No effects as yet reported in 30 million doses of human use
Data on early pregnancy exposure in non-human primates 
being evaluated 
Pregnancy register established in Zambia to monitor effects 
of inadvertent exposure in pgcy
Comparative clinical trials in Thailand with SP to enroll 1600 
patients, 1200 taking AL in 2nd/3rd trimester
No data available on lumefantrine effects,  use AL only in 
2nd and 3rd trimester
Management of severe malaria in 
pregnancy
All trimesters (save mother’s life at all costs)
– Parenteral quinine +/- clindamycin
– Parenteral artemisinins +/- clindamycin
In intensive care – high rate of maternal and 
periantal mortality
– Fluid management
– Prevention / treatment of hypoglycaemia
– Management of premature labour or just labour
– Management of severe anaemia (pulmonary oedema 
may occur)
– Postpartum haemorrhage and risk of death very high
Conclusion
Malaria in pregnancy is a big cause of maternal 
and perinatal morbidity and mortality
There are gaps in knowledge concerning
– development of immunity to malaria, 
– P. vivax infections in pregnancy 
– Effective therapies for both IPTp and case 
management
Programs for the control of malaria in pregnancy 
have not yet been widely and successfully 
implemented. 
WHO recommendations
Areas with <30% PF at Day 14
– Implement IPT with at least 2 doses
– ITNs, treat anaemia, case management
– Evaluate impact of IPT
Areas with 30 – 50% PF at Day 14
– Implement or adopt IPTp policy
– ITNs, treat anaemia, case management
– Evaluate on ongoing basis
Areas with >50% PF at Day 14
– Emphasize control with ITN, anaemia and malaria management
– CT IPT policy and evaluate
– Consider adopting IPTp with SP when evidence of efficacy for 
IPT available in setting
WHO/AFRO/MAL/MIP.IPT/05
SP for IPTp precautions
HIV infected pregnant women taking 
cotrimoxazole for prophylaxis should not receive 
IPT with SP
– Study on efficacy of CTX on PAM on-going
Do not give IPTp with SP to those allergic to 
sulpha drugs
Gambia studies showed no effect of folate 
supplementation on efficacy of SP
Recent data from Siaya however suggests that 
giving SP with high dose folate (1 – 5mg) does 
reduce its efficacy while 400µg does not*
*Ouma P et al (2006) PLoS Clin Trials 1(6) 
IPT future thoughts
Increasing P. falciparum mutations to the 
DHFR gene
Of 5 mutations, 164 is rarest and confers 
total resistance to all anti-folates
Approx: 25% in Thailand, detected in 
western Kenya
Implications for use of candidate drugs for 
IPTp such as chlorproguanil/dapsone, 
atovaquone/proguanil +/- artesunate
ITNs during pregnancy: summary
Variations in study design (gravidity, end point, 
randomization)
Some heterogeneity in efficacy estimates
ITN effects
– Reduce maternal malaria and placental malaria
– Reduce maternal anemia
– Increase mean birth weight
No effect modification by transmission intensity
Effect smaller than with IPT
Take home message: ITNs do prevent adverse 
consequences of malaria during pregnancy, and 
should BE PART of a complete package in ANC
IPTp and ITNs
Combined effect of ITNs and IPT (SP)
– Only one study (Njagi et al, western Kenya)
Both interventions effective
IPT alone >> ITNs alone
Little additional benefit from ITNs over IPT
Neonatal Malaria 
Age old teaching that mother’s antibodies 
protective till at least 12 weeks
Preventive measures – maternal immunity 
changes
0 – 12 weeks also susceptible to malaria 
and must be considered as DD when with 
fever
IMCI?
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